Heemskerk 2018.
Study characteristics | |||
Patient Sampling | Cross‐sectional, consecutive, prospective | ||
Patient characteristics and setting | Presenting signs and symptoms: patients who were offered lumbar puncture as a part of routine care for suspected brain infection Age: ≥ 18 years; median 37 years (IQR 28 to 50) Sex, female: 43% Children: no HIV infection: 31% Clinical setting: multicentre, hospital‐based (both referral and local) Past history of TB: Participants on anti‐TB treatment: Number of specimens evaluated: 610 Laboratory level: central in South Africa Country: South Africa, Vietnam, Indonesia World Bank Income Classification: middle High TB burden: South Africa yes; Vietnam yes; Indonesia yes High TB/HIV burden: South Africa yes; Vietnam no; Indonesia yes High MDR‐TB burden: South Africa yes; Vietnam yes; Indonesia yes |
||
Index tests | Xpert MTB/RIF WHO SOP or manufacturer's protocol followed: no (as performed in Nhu 2014) |
||
Target condition and reference standard(s) | TB meningitis CRS: clinical TB meningitis, diagnosis (definite, probable and possible TB meningitis); MGIT (MODS Indonesia) Speciation yes Decontamination: no |
||
Flow and timing | |||
Comparative | |||
Notes | |||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | Yes | ||
Could the selection of patients have introduced bias? | Low risk | ||
Are there concerns that the included patients and setting do not match the review question? | Low concern | ||
DOMAIN 2: Index Test (Xpert MTB/RIF) | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Could the conduct or interpretation of the index test have introduced bias? | Low risk | ||
Are there concerns that the index test, its conduct, or interpretation differ from the review question? | High | ||
DOMAIN 2: Index Test (Xpert Ultra) | |||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Yes | ||
For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? | |||
Could the reference standard, its conduct, or its interpretation have introduced bias? | Low risk | ||
Are there concerns that the target condition as defined by the reference standard does not match the question? | Low concern | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all patients receive the same reference standard? | Yes | ||
Were all patients included in the analysis? | Yes | ||
Could the patient flow have introduced bias? | Low risk |